Literature DB >> 18690166

Estrogen receptor gene amplification occurs rarely in ovarian cancer.

Rana M Issa1, Annette Lebeau, Tobias Grob, Frederik Holst, Holger Moch, Luigi Terracciano, Matthias Choschzick, Guido Sauter, Ronald Simon.   

Abstract

Amplification of the gene encoding estrogen receptor-alpha occurs in about 20% of breast cancers and is an important mechanism for estrogen receptor overexpression in this tumor type. In ovarian cancer, overexpression of estrogen receptor protein has been described in more than two thirds of cases. To study a potential role of estrogen receptor-alpha gene amplification for estrogen receptor overexpression in ovarian cancer, a tumor tissue microarray containing 428 ovarian cancers was analyzed by fluorescence in situ hybridization for estrogen receptor-alpha gene amplification and immunohistochemistry for estrogen receptor expression. The estrogen receptor-alpha gene status was successfully determined in 243 of 428 arrayed cancers. Estrogen receptor gene amplification was found in 5 of 243 (2%) of tumors. Amplification levels were usually low, with 4-8 estrogen receptor-alpha gene copies. However, one case had a high-level amplification, with more than 30 estrogen receptor-alpha gene copies. All five amplified tumors were estrogen receptor positive, with 3 of 5 tumors showing highest (Allred score, 7-8) estrogen receptor levels. The data demonstrate that estrogen receptor-alpha amplification occurs only rarely in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690166     DOI: 10.1038/modpathol.2008.130

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

2.  Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.

Authors:  Aurelia Noske; Anne-Katrin Zimmermann; Rosmarie Caduff; Zsuzsanna Varga; Daniel Fink; Holger Moch; Glen Kristiansen
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

3.  Minimizing Systematic Errors in Quantitative High Throughput Screening Data Using Standardization, Background Subtraction, and Non-Parametric Regression.

Authors:  Mitas Ray; Keith Shockley; Grace Kissling
Journal:  J Exp Second Sci       Date:  2014-04

4.  ESR1 gene amplification: another mechanism regulating the cellular levels of ERα.

Authors:  Ke-Da Yu; Zhi-Ming Shao
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

Review 5.  The different roles of ER subtypes in cancer biology and therapy.

Authors:  Christoforos Thomas; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

6.  In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer.

Authors:  Yuxin Sun; Yizhuo Xie; Huan Tang; Zhihui Ren; Xue Luan; Yan Zhang; Ming Zhu; Zhe Lv; Han Bao; Yan Li; Rui Liu; Yujia Shen; Yucui Zheng; Jin Pei
Journal:  Int J Nanomedicine       Date:  2021-12-23

7.  An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report.

Authors:  Yue Wang; Shuang Tan; Evenki Pan; Yutong Ma; Xue Wu; Zhe Yu; Kui Jiang
Journal:  Onco Targets Ther       Date:  2022-06-09       Impact factor: 4.345

8.  Molecular genetics complexity impeding research progress in breast and ovarian cancers.

Authors:  Ishita Gupta; Ikram Burney; Mansour S Al-Moundhri; Yahya Tamimi
Journal:  Mol Clin Oncol       Date:  2017-05-29

Review 9.  Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Authors:  Kevin Brasseur; Nicolas Gévry; Eric Asselin
Journal:  Oncotarget       Date:  2017-01-17

Review 10.  ERβ Regulation of Gonadotropin Responses during Folliculogenesis.

Authors:  Eun B Lee; V Praveen Chakravarthi; Michael W Wolfe; M A Karim Rumi
Journal:  Int J Mol Sci       Date:  2021-09-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.